|
IANS File Photo |
NEW DELHI,(IANS): Indian Council
of Medical Research (ICMR) said on Monday Covid-19 vaccine Covaxin neutralises
multiple variants of SARS-CoV-2 and effectively neutralises the double mutant
strain as well.
ICMR
cited the findings of a study carried out by them.
Covaxin is developed
locally by Hyderabad-based Bharat Biotech International Ltd. in collaboration
with the ICMR -- the apex body in India for the formulation, coordination and
promotion of biomedical research.
ICMR-National Institute of Virology has successfully isolated and cultured
multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant),
B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant), said the apex
health research body.
"ICMR
study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and
effectively neutralises the double mutant strain as well," the ICMR said
in a tweet.
They
have also demonstrated the neutralisation potential of Covaxin against the UK variant
and Brazil variant.
ICMR-NIV
recently has been successful in isolating and culturing the double mutant
strain B.1.617 SARS-CoV-2 identified in certain regions of India and several
other countries.
"Covaxin
has been found to effectively neutralise the double mutant strain as
well," it said.
The study was
published in the Journal for Travel Medicine in March where it highlighted that
Covaxin is effective against the UK variants as well as other strains of
Covid-19.
"It was
reassuring from the PRNT50 data generated in our laboratory that the indigenous
BBV152/ COVAXIN, following its roll out in vaccination program, could be
expected to work against the new UK-variant," the study said.
Post a Comment